AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 112 min read$NVO

This Novo Nordisk Analyst Turns Bearish; Here Are Top 4 Downgrades For Friday - Chewy (NYSE:CHWY), Novo N

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight, maintaining a $40 target. JP Morgan downgraded Chewy (CHWY) to Neutral, cutting the target to $24. UBS downgraded NuScale Power (SMR) to Sell, lowering the target to $6. JP Morgan also downgraded Atmos Energy (ATO) to Neutral, reducing the target to $180.

Original reporting
benzinga.com
Published Sep 11, 2026, 1:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NVO
Bearish
medium confidence
Mentioned
$NVO · $CHWY · $SMR · $ATO
Relevance
7/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$NVOBearishMed
01

Why it matters

These downgrades reflect revised expectations and could influence short-term price action.

02

Market read

Four U.S.-listed companies received rating downgrades, suggesting a modest bearish tilt in the market.

03

What to watch

Potential upcoming product launches or contract wins not covered in the downgrade notes.

Relevance 7/10Novelty 7/10Timing: today

Background

Analyst rating changes are common after earnings releases or guidance updates.

Company-level read

Ticker impact

$NVOBearishMedium confidence
Context

Morgan Stanley downgraded Novo Nordisk to Underweight and kept a $40 price target.

Expected impact

Potential short-term decline of 2-4%

Evidence & confidence

Downgrade signals weaker outlook; target below current price.

$CHWYBearishMedium confidence
Context

JP Morgan cut Chewy's price target to $24 and moved rating to Neutral.

Expected impact

Possible 3-5% drop in near term.

Evidence & confidence

Lower target and rating downgrade suggest weaker earnings expectations.

$SMRBearishMedium confidence
Context

UBS downgraded NuScale Power to Sell with a $6 target.

Expected impact

Likely 4-6% slide.

Evidence & confidence

Significant target reduction and sell rating indicate heightened risk.

$ATONeutralLow confidence
Context

JP Morgan moved Atmos Energy to Neutral and cut target to $180.

Expected impact

Flat to slight dip, 1-2% range.

Evidence & confidence

Rating change modest; target still above current price.

Market effects

Sector

Healthcare and consumer discretionary sectors may see modest pressure from analyst downgrades.

Regional

U.S. equities could experience slight pullback in the morning session.

Global

Limited; primarily affects U.S.-listed stocks.

Counterpoint

What could challenge this read

Some investors may view the downgrades as overreactions and look for buying opportunities.

Key entities

  • Analyst Firm
    Morgan Stanley

    Provided downgrade for Novo Nordisk.

  • Analyst Firm
    JP Morgan

    Downgraded Chewy and Atmos Energy.

  • Analyst Firm
    UBS

    Downgraded NuScale Power.

Read at source← All news

Related articles

SEP 12
$NVOMed

Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test

Novo Nordisk (NVO) reported positive results from the STEP Young trial, showing 40.4% of children treated with semaglutide (Wegovy's active ingredient) were no longer classified as obese after 68 weeks. This could expand Wegovy's market, but regulatory approval and adoption remain key uncertainties. NVO faces pressure to find new growth drivers after a setback in the REDEFINE 4 trial.

yahoo.com3 min
SEP 12
$NVOMedAI 8/10

What Do We Actually Know About Kids on Weight-Loss Drugs?

GLP-1 drugs like semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly) are increasingly prescribed off-label for obesity in children. A study found 0.6% of children ages 8-11 were prescribed GLP-1s between 2019-2026, with usage rising yearly. Novo Nordisk's trial showed 40% of children aged 6-12 were no longer obese after 68 weeks of semaglutide treatment. Approval for younger age groups is pending.

gizmodo.com3 min
SEP 12
$NVOMed

Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA

Novo Nordisk (NVO) announced price cuts of up to 50% for Ozempic and Wegovy. Bank of America (BofA) stated this move is unlikely to impact Eli Lilly (LLY)'s GLP-1 business, as most demand comes from cash-paying customers and U.S. government programs. BofA maintained a 'Buy' rating on LLY. NVO's stock fell 3%, LLY's stock dropped 2%. Bloomberg Intelligence's Michael Shah agreed, noting the price cuts benefit specific insurance plans but not net pricing.

stocktwits.com2 min
SEP 11
$CHWYMedAI 8/10

CHWY Stock Hits Over 1-Month Low After Flat Q2 Gross Margin Overshadows Raised Outlook

Chewy Inc. (CHWY) reported Q2 net sales of $3.33B, up 7.3% YoY, meeting estimates. Adjusted EPS rose to $0.36, missing estimates by 1%. Gross margin remained unchanged at 30.4%, while adjusted EBITDA increased 23.7% to $226.7M. Chewy raised its FY26 revenue outlook but narrowed EBITDA margin guidance. CHWY stock fell 7% in morning trade, hitting a one-month low.

stocktwits.com2 min
SEP 11
$CHWYHighAI 9/10

Chewy (CHWY) Is Building a Recurring Revenue Moat Through Autoship and a Vet Care Health Platform

Chewy (CHWY) reported Q2 FY2026 revenue of $3.33B, up 7.3% YoY, with Autoship sales at 84.6% of total. Active customers grew 3.8% YoY to 21.7M. Gross margin was 30.4%, and net income was $80.5M. Management raised full-year guidance, targeting $13.46B-$13.57B in net sales. Chewy Health and Vet Care showed strong growth, with 47 clinics and plans for 10-12 more.

news.alphastreet.com3 min